Production (Stage)
Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -74.11% | -73.59% | -76.80% | -76.25% | 109.96% |
| Total Other Revenue | -30.15% | -28.74% | -17.45% | -15.50% | 36.34% |
| Total Revenue | -64.09% | -63.37% | -69.63% | -68.91% | 86.95% |
| Cost of Revenue | -7.70% | -5.84% | -8.59% | -6.42% | -3.07% |
| Gross Profit | -379.17% | -388.81% | -289.19% | -293.67% | 77.47% |
| SG&A Expenses | 9.74% | 11.94% | 3.62% | 6.08% | -6.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.97% | -1.02% | -5.84% | -3.61% | -4.00% |
| Operating Income | -103.85% | -107.96% | -6,419.71% | -6,577.19% | 48.12% |
| Income Before Tax | -163.39% | -168.69% | -1,525.37% | -1,559.15% | 84.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -163.39% | -168.69% | -1,525.37% | -1,559.15% | 84.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.39% | -168.69% | -1,525.37% | -1,559.15% | 84.81% |
| EBIT | -103.85% | -107.96% | -6,419.71% | -6,577.19% | 48.12% |
| EBITDA | -115.63% | -119.97% | -996.99% | -1,018.29% | 45.68% |
| EPS Basic | -161.45% | -166.67% | -1,520.69% | -1,545.22% | 85.01% |
| Normalized Basic EPS | -161.08% | -166.58% | -1,510.96% | -1,543.06% | 62.33% |
| EPS Diluted | -161.45% | -166.67% | -1,673.58% | -1,672.90% | 85.09% |
| Normalized Diluted EPS | -161.08% | -166.58% | -1,614.71% | -1,605.80% | 62.33% |
| Average Basic Shares Outstanding | 0.80% | 0.80% | 0.69% | 0.69% | 1.33% |
| Average Diluted Shares Outstanding | 0.80% | 0.80% | -5.85% | -3.47% | 1.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |